Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)

HKG:2566 Revenue

Hangzhou Jiuyuan Genetic Biopharmaceutical had revenue of 630.95M CNY in the half year ending June 30, 2026, a decrease of -10.17%. This brings the company's total for the last twelve months to 1.30B, down -0.55% year-over-year. In the year 2025, Hangzhou Jiuyuan Genetic Biopharmaceutical had annual revenue of 1.31B, down -4.59%. That makes Hangzhou Jiuyuan Genetic Biopharmaceutical the 17,795th largest company in the world by revenue and 1,030th in Hong Kong.

• Revenue (ttm): 1.30B CNY
• Revenue Growth: -0.55%
• P/S Ratio: 0.81
• Revenue / Employee: 726.62K CNY
• Employees: 1,787
• Market Cap: 1.11B HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue by Geography

Chart

• Mainland China 1.26B 96.5%
• Other Countries/Regions 45.47M 3.5%

Fiscal year ended Dec 31, 2025 See the full HKG:2566 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.31B	-62.88M	-4.59%
Dec 31, 2024	1.37B	81.78M	6.35%
Dec 31, 2023	1.29B	162.00M	14.40%
Dec 31, 2022	1.13B	-181.85M	-13.91%
Dec 31, 2021	1.31B	-	-

Data Source: S&P Global Market Intelligence Last updated: Sep 23, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 29, 2026

Data Sources Report a data error